Figure 1: Anordrin inhibited tamoxifen-induced mitosis of EECs, as an anti-estrogenic agent in mice uterus.
From: Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity
(a) Paraffin-embedded H&E sections (40x magnifications) of EECs from mice uterus treated by drugs for two weeks. TAM or ANO: mice were treated with tamoxifen (TAM) or anordrin (ANO) alone, respectively. TAM + ANO mice were treated with the combination of tamoxifen and anordrin. Blank mice were treated by vehicle. (b) Statistical analysis of the EEC height (μm), as measured from H&E-stained sections a. Blue bar: mice were administered with tamoxifen (TAM) + anordrin (ANO) (TAM + ANO) at the indicated doses. N = 2 × 6. **means P < 0.01. (c) Anordrin inhibited tamoxifen-induced Hec1A cell proliferation. TAM or ANO: Hec1A cells were treated with 4 μM tamoxifen (TAM) or 4 μM anordrin (ANO) alone, respectively. TAM + ANO: Hec1A cells were treated with 4 μM tamoxifen + 4 μM anordrin. Blank, Hec1A cells were treated by vehicle. N = 3 × 3; **means P < 0.01. (d) H&E staining of uterine EECs of OVX mice. (e) Statistical analysis of the EEC height (μm), as measured from H&E-stained sections d. Two independent experiments were performed with a total of twelve mice for each dose under the same conditions; **means P < 0.01.
